JP2022507830A5 - - Google Patents
Info
- Publication number
- JP2022507830A5 JP2022507830A5 JP2021527959A JP2021527959A JP2022507830A5 JP 2022507830 A5 JP2022507830 A5 JP 2022507830A5 JP 2021527959 A JP2021527959 A JP 2021527959A JP 2021527959 A JP2021527959 A JP 2021527959A JP 2022507830 A5 JP2022507830 A5 JP 2022507830A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769987P | 2018-11-20 | 2018-11-20 | |
| US62/769,987 | 2018-11-20 | ||
| US201862774595P | 2018-12-03 | 2018-12-03 | |
| US62/774,595 | 2018-12-03 | ||
| US201962795810P | 2019-01-23 | 2019-01-23 | |
| US62/795,810 | 2019-01-23 | ||
| US201962828770P | 2019-04-03 | 2019-04-03 | |
| US62/828,770 | 2019-04-03 | ||
| US201962846563P | 2019-05-10 | 2019-05-10 | |
| US62/846,563 | 2019-05-10 | ||
| US201962848961P | 2019-05-16 | 2019-05-16 | |
| US62/848,961 | 2019-05-16 | ||
| US16/445,965 US10918667B2 (en) | 2018-11-20 | 2019-06-19 | Modified cell expressing therapeutic agent and uses thereof |
| US16/445,965 | 2019-06-19 | ||
| US201962889926P | 2019-08-21 | 2019-08-21 | |
| US62/889,926 | 2019-08-21 | ||
| US201962902766P | 2019-09-19 | 2019-09-19 | |
| US62/902,766 | 2019-09-19 | ||
| PCT/US2019/062417 WO2020106843A1 (en) | 2018-11-20 | 2019-11-20 | Modified cell expressing therapeutic agent and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507830A JP2022507830A (ja) | 2022-01-18 |
| JPWO2020106843A5 JPWO2020106843A5 (https=) | 2022-11-29 |
| JP2022507830A5 true JP2022507830A5 (https=) | 2022-11-29 |
Family
ID=70774027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527959A Pending JP2022507830A (ja) | 2018-11-20 | 2019-11-20 | 治療薬を発現する改変細胞とその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20220000921A1 (https=) |
| EP (1) | EP3883585A4 (https=) |
| JP (1) | JP2022507830A (https=) |
| AU (1) | AU2019384145A1 (https=) |
| CA (1) | CA3120153A1 (https=) |
| SG (1) | SG11202105173VA (https=) |
| WO (1) | WO2020106843A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| EP3810640A1 (en) * | 2018-06-25 | 2021-04-28 | University of Washington | De novo design of potent and selective interleukin mimetics |
| WO2020028275A1 (en) * | 2018-07-30 | 2020-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Interferon-gamma biased agonists |
| JP7156653B2 (ja) | 2018-08-30 | 2022-10-19 | イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ | 固形腫瘍を治療するためのキメラ抗原受容体細胞 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| EP3883956A1 (en) | 2018-11-20 | 2021-09-29 | University of Washington | Split interleukin mimetics and their use |
| JP2022531814A (ja) * | 2019-03-12 | 2022-07-12 | イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ | 改変細胞の増幅およびその応用 |
| AU2020315800A1 (en) | 2019-07-19 | 2022-03-03 | Seneca Therapeutics, Inc. | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
| US20210060069A1 (en) * | 2019-08-23 | 2021-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Coupled redirected cells and uses thereof |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| WO2021179967A1 (zh) * | 2020-03-09 | 2021-09-16 | 四川大学华西医院 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
| EP3892720A1 (en) | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| KR20230040364A (ko) * | 2020-07-27 | 2023-03-22 | 센터 포 엑설런스 인 몰레큘러 셀 사이언스, 차이니즈 아카데미 오브 사이언시스 | 키메라 항원 수용체 및 이의 용도 |
| WO2022038264A1 (en) * | 2020-08-21 | 2022-02-24 | Julius-Maximilians-Universität Würzburg | Modified lymphocytes |
| JP2023545126A (ja) * | 2020-10-12 | 2023-10-26 | 武田薬品工業株式会社 | Ｃａｒ－ｔ細胞の細胞動態及び体内分布の決定 |
| WO2022159508A1 (en) * | 2021-01-19 | 2022-07-28 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
| US11633427B2 (en) * | 2021-02-05 | 2023-04-25 | Innovative Cellular Therapeutics Holdings, Ltd. | Vaccine and uses thereof in cell therapy |
| CN113046320B (zh) * | 2021-02-19 | 2023-04-14 | 中国医学科学院基础医学研究所 | 胞外段为Vδ1(GTM)Vγ4的CAR分子及表达该分子的CAR-T细胞及其用途 |
| CN114934071B (zh) * | 2021-04-30 | 2023-10-17 | 四川大学华西医院 | 一种表达免疫调节因子的car载体及其应用 |
| EP4215245A1 (en) | 2022-01-19 | 2023-07-26 | Innovative Cellular Therapeutics Holdings, Ltd. | Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment |
| AU2024289944A1 (en) | 2023-07-05 | 2026-01-29 | Nanotein Technologies, Inc. | Cell signaling complexes and uses thereof |
| US12473529B2 (en) | 2023-07-18 | 2025-11-18 | Nanotein Technologies, Inc. | Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof |
| WO2025117789A1 (en) * | 2023-12-01 | 2025-06-05 | Parker Institute For Cancer Immunotherapy | Engineered immune signaling constructs |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
| WO2025184172A1 (en) * | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Cancer reactive t cell receptors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ508878A (en) * | 1998-05-15 | 2003-08-29 | Genentech Inc | IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells |
| SK8292002A3 (en) * | 1999-11-12 | 2002-12-03 | Maxygen Holdings Ltd | A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof |
| AUPQ755300A0 (en) * | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
| US7038015B2 (en) * | 2001-04-06 | 2006-05-02 | Maxygen Holdings, Ltd. | Interferon gamma polypeptide variants |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP1572242B1 (en) * | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| WO2010081738A1 (en) * | 2009-01-16 | 2010-07-22 | Agirx Limited | Vaccine compositions |
| AU2010241864B2 (en) * | 2009-04-30 | 2014-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| AU2011239569B2 (en) * | 2010-04-16 | 2014-07-24 | Baylor College Of Medicine | Method for treating solid tumors |
| EP2640404B1 (en) * | 2010-11-17 | 2017-02-22 | Ben Gurion University of The Negev Research and Development Authority | T-cell therapy to neurodegenerative diseases |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) * | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| AU2012267710A1 (en) * | 2011-06-08 | 2014-01-23 | The Regents Of The University Of California | Anti-CD22 antigen binding molecules to treat lung cancer and prostate cancer |
| WO2013059593A1 (en) * | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| US11382963B2 (en) * | 2015-01-12 | 2022-07-12 | Pieris Pharmaceuticals Gmbh | Engineered T cells and uses therefor |
| US10493139B2 (en) * | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| CN108243607A (zh) * | 2015-09-09 | 2018-07-03 | 西雅图儿童医院（Dba西雅图儿童研究所） | 用于免疫疗法的巨噬细胞的遗传工程 |
| JP7115982B2 (ja) * | 2015-10-30 | 2022-08-09 | アレタ・バイオセラピューティクス・インコーポレイテッド | 癌の治療のための組成物及び方法 |
| AU2017225733A1 (en) * | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore |
| CN109219445B (zh) * | 2016-04-01 | 2022-08-26 | 上海煦顼技术有限公司 | 嵌合抗原受体修饰细胞治疗癌症的应用 |
| US11377637B2 (en) * | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| WO2017186121A1 (zh) * | 2016-04-26 | 2017-11-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| WO2018064921A1 (en) * | 2016-10-06 | 2018-04-12 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| WO2018136566A1 (en) * | 2017-01-18 | 2018-07-26 | F1 Oncology, Inc. | Methods of transducing and expanding immune cells and uses thereof |
| US10561686B2 (en) * | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
-
2019
- 2019-11-20 EP EP19887928.0A patent/EP3883585A4/en not_active Withdrawn
- 2019-11-20 JP JP2021527959A patent/JP2022507830A/ja active Pending
- 2019-11-20 US US17/295,364 patent/US20220000921A1/en active Pending
- 2019-11-20 AU AU2019384145A patent/AU2019384145A1/en not_active Abandoned
- 2019-11-20 CA CA3120153A patent/CA3120153A1/en active Pending
- 2019-11-20 WO PCT/US2019/062417 patent/WO2020106843A1/en not_active Ceased
- 2019-11-20 SG SG11202105173VA patent/SG11202105173VA/en unknown
-
2022
- 2022-05-20 US US17/749,824 patent/US20220339193A1/en active Pending